NCAM1 and Miyoshi myopathy: Other possible solutions to overcome this problem could be to focus on other markers; tests were been done using CD138, whose expression seems to deteriorate over time; CD56, which is not always present on MM PCs; or new markers such as VS38 that, used in place of normal CD38, seems to also have brighter expression in MM PC recognition in patients who started anti-CD38 therapy [21].